Healthcare utilization and direct medical cost in the years during and after cancer diagnosis in patients with type 2 diabetes mellitus
Open Access
- 29 May 2020
- journal article
- research article
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 11 (6) , 1661-1672
Abstract
Aims/Introduction: There is uncertainty about the direct medical costs of type 2 diabetes patients with cancers.Materials and Methods: A population‐based retrospective cohort of 99,915 type 2 diabetes patients from the Hong Kong Hospital Authority between 2006 and 2017 was assembled. A total of 16,869 patients who had an initial cancer diagnosis after type 2 diabetes diagnosis were matched with 83,046 patients without cancer (controls) using a matching ratio of up to one‐to‐five propensity score‐matching method. Patients were divided into four categories according to life expectancy. Healthcare service utilization and direct medical costs during the index year, subsequent years and mortality year were compared between patients with and without cancer in each category.Results: Medical costs of cancer patients in the index year ranged from $US27,533 for patients who died in 3 years. Cancer patients had significantly greater expenditures than controls in the index year (all P < 0.001) and subsequent years ($US4,569 vs $US4,155, P < 0.001). Cancer patients also had greater costs in the year of death, and the difference was significant for patients who survived >3 years after the index year ($US32,558 vs $US28,260). For patients in both groups, patients who survived >3 years had significantly lower costs than those who died in 90% of the medical costs for both groups in the mortality year.Conclusions: Type 2 diabetes patients with cancers incurred greater medical costs in the diagnosis, ensuing and mortality years than type 2 diabetes patients without cancers.Keywords
Funding Information
- Health and Medical Research Fund (02160087)
This publication has 35 references indexed in Scilit:
- Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk FactorsJournal of Cancer Epidemiology, 2013
- Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta‐analysisDiabetes/Metabolism Research and Reviews, 2012
- Diabetes, cancer, and metformin: connections of metabolism and cell proliferationAnnals of the New York Academy of Sciences, 2011
- Economic Burden of Cancer in the United States: Estimates, Projections, and Future ResearchCancer Epidemiology, Biomarkers & Prevention, 2011
- Multiple imputation using chained equations: Issues and guidance for practiceStatistics in Medicine, 2010
- Diabetes and CancerDiabetes Care, 2010
- Diabetes mellitus and risk of breast cancer: A meta‐analysisInternational Journal of Cancer, 2007
- Diabetes Mellitus and Risk of Colorectal Cancer: A Meta-AnalysisJNCI: Journal of the National Cancer Institute, 2005
- Estimating the Cost of Cancer: Results on the Basis of Claims Data Analyses for Cancer Patients Diagnosed With Seven Types of Cancer During 1999 to 2000Journal of Clinical Oncology, 2004
- Guidelines for Computer Modeling of Diabetes and Its ComplicationsDiabetes Care, 2004